MOESM2 of Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

Additional file 2: Table S1. Clinical features of 378 patients in the training and validation cohort whose DLBCL biopsies were sequenced and 290 patients whose sequencing results showed sufficient sequence reads. Table S2. Comparisons of clinicopathologic and molecular characteristics between patients with germinal-center B-cell–like (GCB) DLBCL with a low or high degree of somatic hypermutation (SHM) in immunoglobulin variable region genes. Table S3. Comparisons of clinicopathologic and molecular characteristics between patients with activated B-cell-like (ABC) subtype of DLBCL with a low or high degree of SHM in immunoglobulin variable region genes. Table S4. Significant prognostic effects of immunoglobulin molecular characteristics in DLBCL patients treated with R-CHOP by multivariate survival analysis. Table S5. Clinicopathologic and molecular characteristics of patients with DLBCL with a short or long immunoglobulin heavy/light chain CDR3 length. Table S6. Clinicopathologic and molecular characteristics of patients with DLBCL with ongoing SHM in immunoglobulin variable region genes. Table S7. Gene signatures associated with SHM in immunoglobulin sequences of DLBCL samples. Table S8. Multiple testing corrections for prognostic effects found in the overall cohort of DLBCL treated with R-CHOP by the Benjamini-Hochberg method with a false discovery rate of 0.10